tiprankstipranks
KalVista Nosedives after Terminating Phase 2 HAE Trial
Market News

KalVista Nosedives after Terminating Phase 2 HAE Trial

Shares of KalVista Pharmaceuticals (NASDAQ:KALV) are tanking today after the company terminated the Phase 2 trial of KVD824 for treating hereditary angioedema (HAE).

The termination was based on elevated liver enzyme (ALT/AST) in patients across all treatment groups of the study.

Separately, the company continues to recruit for the Phase 3 trial of sebetralstat for the treatment of HAE attacks. Data from the study is expected in H2 2023.

Is KALV Stock a Good Buy?

KALV stock has declined nearly 61.3% over the past month. Nonetheless, four unanimous Buy ratings point to a Strong Buy consensus rating for the stock alongside an average price target of $43.75.

This implies a massive 616.04% upside potential for the stock.

Disclosure

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles